| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma
|
Zhao, Binghao
|
|
|
22 |
8 |
p. e345
|
artikel
|
| 2 |
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply
|
van den Bent, Martin J
|
|
|
22 |
8 |
p. e346
|
artikel
|
| 3 |
Alcohol and the global burden of cancer: what are we missing?
|
Justice, Amy C
|
|
|
22 |
8 |
p. 1048-1049
|
artikel
|
| 4 |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose, Marcia S
|
|
|
22 |
8 |
p. 1126-1138
|
artikel
|
| 5 |
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
|
Yang, Yunpeng
|
|
|
22 |
8 |
p. 1162-1174
|
artikel
|
| 6 |
CanStaging+: an electronic staging tool for population-based cancer registries
|
Soerjomataram, Isabelle
|
|
|
22 |
8 |
p. 1069
|
artikel
|
| 7 |
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
|
Denkert, Carsten
|
|
|
22 |
8 |
p. 1151-1161
|
artikel
|
| 8 |
Correction to Lancet Oncol 2021; 22: 977–90
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 9 |
Correction to Lancet Oncol 2021; 22: 959–69
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 10 |
Correction to Lancet Oncol 2021; 22: 1061
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 11 |
Correction to Lancet Oncol 2021; 22: 919–30
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 12 |
Correction to Lancet Oncol 2021; 22: 1081–92
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 13 |
Correction to Lancet Oncol 2019; 20: 1211–25
|
|
|
|
22 |
8 |
p. e347
|
artikel
|
| 14 |
COVID-19 pandemic causes cervical cancer screening crisis
|
Gourd, Elizabeth
|
|
|
22 |
8 |
p. 1060
|
artikel
|
| 15 |
Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial
|
Vos, Julien A M
|
|
|
22 |
8 |
p. 1175-1187
|
artikel
|
| 16 |
Elective nodal radiotherapy in prostate cancer
|
De Meerleer, Gert
|
|
|
22 |
8 |
p. e348-e357
|
artikel
|
| 17 |
ESMO World Congress on Gastrointestinal Cancer 2021
|
Gourd, Katherine
|
|
|
22 |
8 |
p. 1062
|
artikel
|
| 18 |
Expanding access to childhood and AYA cancer care
|
The Lancet Oncology,
|
|
|
22 |
8 |
p. 1047
|
artikel
|
| 19 |
Getting back on track with HPV vaccination to prevent cancer
|
Das, Manjulika
|
|
|
22 |
8 |
p. 1059
|
artikel
|
| 20 |
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
|
Rumgay, Harriet
|
|
|
22 |
8 |
p. 1071-1080
|
artikel
|
| 21 |
HER2: a never ending story
|
Dieci, Maria Vittoria
|
|
|
22 |
8 |
p. 1051-1052
|
artikel
|
| 22 |
Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses
|
Fueyo, Juan
|
|
|
22 |
8 |
p. 1049-1051
|
artikel
|
| 23 |
Improving single-agent chemoresistance risk identification in gestational trophoblastic neoplasia
|
Ferrandina, Gabriella
|
|
|
22 |
8 |
p. 1054-1056
|
artikel
|
| 24 |
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
|
Li, Mengqian
|
|
|
22 |
8 |
p. e342
|
artikel
|
| 25 |
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply
|
da Silva, Ines Pires
|
|
|
22 |
8 |
p. e343-e344
|
artikel
|
| 26 |
Lebanon faces critical shortage of drugs
|
Das, Manjulika
|
|
|
22 |
8 |
p. 1063
|
artikel
|
| 27 |
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
|
Fares, Jawad
|
|
|
22 |
8 |
p. 1103-1114
|
artikel
|
| 28 |
Neuroendocrine tumour of the gallbladder
|
Bhatia, Harsimran
|
|
|
22 |
8 |
p. e377
|
artikel
|
| 29 |
New radiation health standard required for deep space travel
|
Gourd, Elizabeth
|
|
|
22 |
8 |
p. 1065
|
artikel
|
| 30 |
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
|
Gafita, Andrei
|
|
|
22 |
8 |
p. 1115-1125
|
artikel
|
| 31 |
Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
|
Zhang, Nan
|
|
|
22 |
8 |
p. e358-e368
|
artikel
|
| 32 |
Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer
|
Huynh, Caroline
|
|
|
22 |
8 |
p. 1056-1058
|
artikel
|
| 33 |
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|
Zhang, Xiaotian
|
|
|
22 |
8 |
p. 1081-1092
|
artikel
|
| 34 |
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study
|
Braga, Antonio
|
|
|
22 |
8 |
p. 1188-1198
|
artikel
|
| 35 |
RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
|
Zhu, Xiaofei
|
|
|
22 |
8 |
p. 1093-1102
|
artikel
|
| 36 |
Serbia faces bleak cancer situation
|
Das, Manjulika
|
|
|
22 |
8 |
p. 1064
|
artikel
|
| 37 |
Should stereotactic radiotherapy be the preferred treatment for oligometastatic disease?
|
Palma, David
|
|
|
22 |
8 |
p. 1067-1068
|
artikel
|
| 38 |
The challenges of cancer care for the LGBTQ+ community
|
Burki, Talha Khan
|
|
|
22 |
8 |
p. 1061
|
artikel
|
| 39 |
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research
|
Ranganathan, Priya
|
|
|
22 |
8 |
p. e369-e376
|
artikel
|
| 40 |
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
|
|
|
|
22 |
8 |
p. 1139-1150
|
artikel
|
| 41 |
UK Government urged to prioritise improvements to NHS imaging services
|
Burki, Talha Khan
|
|
|
22 |
8 |
p. 1066
|
artikel
|
| 42 |
Verna Vanderpuye—special mentor for cancer care in Africa
|
Morgan, Jules
|
|
|
22 |
8 |
p. 1070
|
artikel
|
| 43 |
Who should manage post-treatment care for patients with colon cancer: surgeons or general practitioners?
|
Angenete, Eva
|
|
|
22 |
8 |
p. 1053-1054
|
artikel
|
Tijdschrift beschrijving